Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 2/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.41 |
| ▸ | PAM | P19021 | 1/20 | 0.41 |
| ▸ | EHMT2 | Q96KQ7 | 1/20 | 0.41 |
| ▸ | EHMT1 | Q9H9B1 | 1/20 | 0.41 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 2/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.40 |
| ▸ | MTNR1B | P49286 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20998952 | 1.00 | ALDH1A1 (0.45) | ALDH1A1SMN1; SMN2HDAC1HDAC2HPGD | |
| SCHEMBL24378432 | 0.88 | HDAC1 (0.48) | ALDH1A1SMN1; SMN2HDAC1HDAC2HPGD | |
| SCHEMBL9915159 | 0.87 | HDAC1 (0.42) | ALDH1A1SMN1; SMN2HDAC1HDAC2HPGD | |
| SCHEMBL20885060 | 0.86 | EHMT2 (0.43) | ALDH1A1SMN1; SMN2HDAC1HDAC2HPGD | |
| SCHEMBL30616153 | 0.85 | LMNA (0.48) | ALDH1A1SMN1; SMN2HDAC1HDAC2MEN1 | |
| SCHEMBL24378375 | 0.85 | LMNA (0.48) | ALDH1A1SMN1; SMN2HDAC1HDAC2MEN1 | |
| SCHEMBL29092878 | 0.85 | LMNA (0.48) | ALDH1A1SMN1; SMN2HDAC1HDAC2MEN1 | |
| SCHEMBL14984799 | 0.83 | PPARA (0.55) | HDAC1HDAC2 | |
| SCHEMBL25800370 | 0.83 | HDAC1 (0.42) | ALDH1A1SMN1; SMN2HDAC1HDAC2EHMT2 | |
| SCHEMBL13225865 | 0.82 | HDAC1 (0.48) | SMN1; SMN2HDAC1HDAC2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119638607-A | Sulfide prodrug based on butylphthalide as carrier | 中国药科大学 | 2025-03-18 | — | — | CN | disclosed |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-12-14 | — | — | US | disclosed |
| CN-116940570-A | Compounds and methods for treating ocular disorders | 阿祖拉眼科有限公司 | 2023-10-24 | — | — | CN | disclosed |
| EP-4232149-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2023-08-30 | — | — | EP | disclosed |
| EP-4232034-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | AZURA OPHTHALMICS LTD (IL) | 2023-08-30 | — | — | EP | disclosed |
| CN-116635032-A | Compounds and methods for treating ocular disorders | 阿祖拉眼科有限公司 | 2023-08-22 | — | — | CN | disclosed |
| US-20220332749-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-10-20 | — | — | US | disclosed |
| WO-2022084738-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084739-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084739-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022084738-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230399317-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | ALDH1A1 489/4885SMN1; SMN2 4754/4885HDAC1 1658/4885 |
| US-20220332749-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | MPO, MUC1, CRYAB | ALDH1A1 489/4885SMN1; SMN2 4754/4885HDAC1 1658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.